Cardiogenic Shock

Cardiac Intensive Care

Volumn , Issue , 2010, Pages 212-224

  Bates, Eric R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882842638     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3773-6.10017-5     Document Type: Chapter

References (102)

1. Killip T., Kimball T. Treatment of myocardial infarction in a coronary care unit. Am J Cardiol 1967, 20:457.
2. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1988, 1:545.
3. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo controlled clinical trial. Lancet 1988, 1:545. AIMS Trial Study Group.
4. Wilcox R.G., Olsson C.G., Skene A.M., et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988, 2:545.
5. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988, 2:349. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
6. Fishberg A.M., Hitzig W.M., King F.H. Circulatory dynamics in myocardial infarction. Arch Intern Med 1934, 54:997.
7. Stead E.A., Ebert R.V. Shock syndrome produced by failure of the heart. Arch Intern Med 1942, 69:369.
8. Griffith G.C., Wallace W.B., Cochran B., et al. The treatment of shock associated with myocardial infarction. Circulation 1954, 9:527.
9. Kantrowitz A., Tjonneland S., Krakauer J.S., et al. Mechanical intraaortic cardiac assistance in cardiogenic shock. Arch Surg 1968, 97:1000.
10. Dunkman W.B., Leinbach R.C., Buckley M.J., et al. Clinical and hemodynamic results of intraaortic balloon pumping and surgery for cardiogenic shock. Circulation 1972, 47:465.
11. Scheidt S., Wilner G., Mueller H., et al. Intra-aortic balloon counterpulsation in cardiogenic shock: report of a cooperative clinical trial. N Engl J Med 1973, 188:979.
12. Forrester J.S., Diamond G., Chatterjee K., et al. Medical therapy of acute myocardial infarction by application of hemodynamic subsets. N Engl J Med 1976, 195:1356.
13. DeWood M.A., Notske R.N., Hensley G.R., et al. Intra-aortic balloon counterpulsation with and without reperfusion for myocardial infarction shock. Circulation 1980, 61:1105.
14. Mathey D., Kuck K.H., Remmecke J., et al. Transluminal recanalization of coronary artery thrombosis: a preliminary report of its application in cardiogenic shock. Eur Heart J 1980, 1:207.
15. Meyer J., Merx W., Dörr R., et al. Successful treatment of acute myocardial infarction shock by combined percutaneous transluminal coronary recanalization (PTCR) and percutaneous transluminal coronary angioplasty (PTCA). Am Heart J 1982, 103:132.
16. Lee L., Bates E.R., Pitt B., et al. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation 1988, 78:1345.
17. Hochman J.S., Sleeper L.A., Webb J.G., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?. N Engl J Med 1999, 341:625.
18. Hochman J.S., Sleeper L.A., White H.D., et al. One-year survival following early revascularization for cardiogenic shock. JAMA 2001, 285:190.
19. Hochman J.S., Sleeper L.A., Webb J.G., et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006, 295:2511.
20. Menon V., White H., LeJemtel T., et al. The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK?. J Am Coll Cardiol 2000, 36:1071.
21. Jacobs A.K., Leopold J.A., Bates E., et al. Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry. J Am Coll Cardiol 2003, 41:1273.
22. Thompson C.R., Buller C.E., Sleeper L.A., et al. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we use emergently revascularize Occluded Coronaries in cardiogenic shocK?. J Am Coll Cardiol 2000, 36:1104.
23. Menon V., Webb J.G., Hillis L.D., et al. Outcome and profile of ventricular septal rupture with cardiogenic shock after myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol 2000, 36:1110.
24. Slater J., Brown R.J., Antonelli T.A., et al. Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol 2000, 36:1117.
25. Goldberg R.J., Samad N.A., Yarzebski J., et al. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999, 340:1162.
26. Babaev A., Frederick P.D., Pasta D.J., et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005, 294:448.
27. Holmes D.R., Berger P.B., Hochman J.S., et al. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation 1999, 100:2067.
28. Jacobs A.K., French J.K., Col J., et al. Cardiogenic shock with non-ST-segment elevation myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded coronaries for Cardiogenic shocK?. J Am Coll Cardiol 2000, 36:1091.
29. Webb J.G., Sleeper L.A., Buller C.E., et al. Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?. J Am Coll Cardiol 2000, 36:1084.
30. Menon V., Slater J.N., White H.D., et al. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry. Am J Med 2000, 108:374.
31. Williams D.O., Amsterdam E.Z., Miller R.R., et al. Functional significance of coronary collateral vessels in patients with acute myocardial infarction: relation to pump performance, cardiogenic shock and survival. Am J Cardiol 1976, 37:345.
32. Sanborn T.A., Sleeper L.A., Webb J.G., et al. Correlates of one-year survival in patients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial. J Am Coll Cardiol 2003, 42:1373.
33. Page D.L., Caufield J.B., Kaster J.A., et al. Myocardial changes associated with cardiogenic shock. N Engl J Med 1971, 285:133.
34. Alonso D.R., Scheidt S., Post M., et al. Pathophysiology of cardiogenic shock: quantitation of myocardial necrosis, clinical, pathologic and electrocardiographic correlations. Circulation 1973, 48:588.
35. Grines C.L., Topol E.J., Califf R.M., et al. Prognostic implications and predictors of enhanced regional wall motion of the noninfarct zone after thrombolysis and angioplasty therapy of acute myocardial infarction. Circulation 1989, 80:245.
36. Hochman J.S. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003, 107:2998.
37. Hands M.E., Rutherford J.D., Muller J.E., et al. The in-hospital development of cardiogenic shock after myocardial infarction: incidence, predictors of occurrence, outcome and prognostic factors. J Am Coll Cardiol 1989, 14:40.
38. Leor J., Goldbourd U., Reicher-Reiss H., et al. Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: incidence, risk factors and outcome. SPRINT study group. Am J Med 1993, 94:256.
39. Fincke R., Hochman J.S., Lowe A., et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol 2004, 44:340-348.
40. Mueller H., Ayres I.A., Giannelli S., et al. Effect of isoproterenol, L-norepinephrine, and intraaortic counterpulsation on hemodynamics and myocardial metabolism in shock following acute myocardial infarction. Circulation 1972, 45:335.
41. Weiss A.T., Engle S., Gotsman C.J. Regional and global left ventricular function during intra-aortic balloon counterpulsation in patients with acute myocardial infarction shock. Am Heart J 1984, 108:249.
42. Port S.C., Shantilal P., Schmidt D.M. Effects of intraaortic balloon counterpulsation on myocardial blood flow in patients with severe coronary artery disease. J Am Coll Cardiol 1984, 3:1367.
43. O'Rourke M.F., Norris R.M., Campbell T.J., et al. Randomized controlled trial of intraaortic balloon counterpulsation in early myocardial infarction with acute heart failure. Am J Cardiol 1989, 47:815.
44. Anderson R.D., Ohman E.M., Holmes D.R., et al. Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. J Am Coll Cardiol 1997, 30:708.
45. Kovach P.J., Rasak M.A., Bates E.R. Thrombolysis plus aortic counterpulsation: improved survival in patients who present to community hospitals with cardiogenic shock. J Am Coll Cardiol 1997, 29:1454.
46. Sanborn T.A., Sleeper L.A., Bates E.R., et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol 2000, 36:1123.
47. Barron H.V., Every N.R., Parsons L.S., et al. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J 2001, 141:933.
48. Ohman E.M., Nanas J., Stomel R.J., et al. Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS Trial. J Thromb Thrombolysis 2005, 19:33.
49. Ohman E.M., George B.S., White C.J., et al. Use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction: results of a randomized trial. The Randomized IABP Study Group. Circulation 1994, 90:792.
50. Ishihara M., Sato H., Tateishi H., et al. Intraaortic balloon pumping as adjunctive therapy to rescue coronary angioplasty after failed thrombolysis in anterior wall acute myocardial infarction. Am J Cardiol 1995, 76:73.
51. Stone G.W., Marsalese D., Brodie B.R., et al. A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. J Am Coll Cardiol 1997, 29:1459.
52. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004, 110:e82.
53. Vogel R.A., Shawl F., Tommaso C., et al. Initial report of the National Registry of Elective Cardiopulmonary Bypass Supported Coronary Angioplasty. J Am Coll Cardiol 1990, 15:23.
54. Nichol G., Karmy-Jones R., Salerno C., et al. Systematic review of percutaneous cardiopulmonary bypass for cardiac arrest or cardiogenic shock states. Resuscitation 2006, 70:381.
55. Bartlett R.H., Roloff D.W., Custer J.R., et al. Extracorporeal life support: the University of Michigan experience. JAMA 2000, 283:904.
56. Thiele H., Smalling R.W., Schuler G.C. Percutaneous left ventricular assist devices in acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2007, 28:2057.
57. Thiele H., Lauer B., Hambrecht R., et al. Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation 2001, 104:2917.
58. Atiemo A.D., Conte J.V., Heldman A.W. Resuscitation and recovery from acute right ventricular failure using a percutaneous right ventricular assist device. Catheter Cardiovasc Interv 2006, 68:78.
59. Thiele H., Sick P., Boudriot E., et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005, 26:1276.
60. Magliato K.E., Kleisli T., Soukiasian H.J., et al. Biventricular support in patients with profound cardiogenic shock: a single center experience. Asaio J 2003, 49:475.
61. Bates E.R., Topol E.J. Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol 1991, 18:1077.
62. Kennedy J., Gensini G., Timmis G., et al. Acute myocardial infarction treated with intracoronary streptokinase: a report of the Society for Cardiac Angiography. Am J Cardiol 1985, 55:871.
63. Meinertz T., Kasper W., Schumacher M., Just H. The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction. Am J Cardiol 1988, 62:347.
64. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990, 336:71. The International Study Group.
65. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992, 339:753. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.
66. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997, 337:1118. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators.
67. Neuhaus K.L., von Essen R., Tebbe U., et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol 1992, 19:885.
68. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993, 329:673. GUSTO investigators.
69. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995, 346:329. International Joint Efficacy Comparison of Thrombolytics.
70. Becker R.C. Hemodynamic, mechanical, and metabolic determinants of thrombolytic efficacy: a theoretic framework for assessing the limitations of thrombolysis in patients with cardiogenic shock. Am Heart J 1993, 125:919.
71. Prewitt R.M., Gu S., Garber P.J., et al. Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992, 20:1626.
72. Prewitt R.M., Gu S., Schick U., et al. Intraaortic balloon counterpulsation enhances coronary thrombolysis induced by intravenous administration of a thrombolytic agent. J Am Coll Cardiol 1994, 23:794.
73. O'Neill W.W., Erbel R., Laufer N., et al. Coronary angioplasty therapy of cardiogenic shock complicating acute myocardial infarction [Abstract]. Circulation 1985, 72(Suppl II):309.
74. Brown T.M., Jannone L.A., Gordon D.F., et al. Percutaneous myocardial reperfusion reduces mortality in acute myocardial infarction complicated by cardiogenic shock [Abstract]. Circulation 1985, 72(Suppl III):309.
75. Holmes D.R., Bates E.R., Kleiman N.S., et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-1 trial experience. J Am Coll Cardiol 1995, 26:668.
76. Berger P.B., Holmes D.R., Stebbins A., et al. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-1). Trial. Circulation 1997, 96:122.
77. Zeymer U., Vogt A., Zahn R., et al. Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI): results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK). Eur Heart J 2004, 25:322.
78. Hochman J.S., Boland J., Sleeper A.L., et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality: results of an international registry. Circulation 1995, 91:873.
79. Urban P., Stauffer J.C., Bleed D., et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. Eur Heart J 1999, 20:1030.
80. Hochman J.S., Buller C.E., Sleeper L.A., et al. Cardiogenic shock complicating acute myocardial infarction-etiologies, management and outcome: a report from the SHOCK trial registry. J Am Coll Cardiol 2000, 336:1063.
81. Dzavik V., Sleeper L.A., Cocke T.P., et al. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J 2003, 24:828.
82. Antoniucci D., Valenti R., Migliorini A., et al. Comparison of impact of emergency percutaneous revascularization on outcome of patients > or =75 to those < 75 years of age with acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 2003, 91:1458.
83. Dauerman H.L., Ryan T.J., Piper W.D., et al. Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter, decade-long experience. J Invasive Cardiol 2003, 15:380.
84. Prasad A., Lennon R.J., Rihal C.S., et al. Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularization. Am Heart J 2004, 147:1066.
85. Zhu M.M., Feit A., Chadow H., et al. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol 2001, 88:297.
86. Antoniucci D., Valenti R., Santoro G.M., et al. Systematic direct angioplasty and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: in-hospital and long-term survival. J Am Coll Cardiol 1998, 31:294.
87. Chan A.W., Chew D.P., Bhatt D.L., et al. Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 2002, 89:132.
88. Huang R., Sacks J., Thai H., et al. Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention. Catheter Cardiovasc Interv 2005, 65:25.
89. Yip H.K., Wu C.J., Chang H.W., et al. Comparison of impact of primary percutaneous transluminal coronary angioplasty and primary stenting on short-term mortality in patients with cardiogenic shock and evaluation of prognostic determinants. Am J Cardiol 2001, 87:1184.
90. Giri S., Mitchel J., Azar R.R., et al. Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 2002, 89:126.
91. De Luca G., Suryapranata H., Stone G.W., et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005, 293:1759.
92. Antoniucci D., Valenti R., Migliorini A., et al. Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation. Am J Cardiol 2002, 90:353.
93. Champagnac D., Claudel J.P.H., Desseigne P., et al. Primary cardiogenic shock during acute myocardial infarction: results of emergency cardiac transplantation. Eur Heart J 1993, 14:925.
94. Hochman J.S. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003, 107:2998.
95. Cotter G., Kaluski E., Blatt A., et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 2000, 101:1358.
96. Cotter G., Kaluski E., Milovanov O., et al. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J 2003, 24:1287.
97. Dzavik V., Cotter G., Reynolds H.R., et al. Effect of nitric oxide synthase inhibition on hemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. Eur Heart J 2007, 28:1009.
98. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock. The TRIUMPH randomized controlled trial. JAMA 2007, 297:1657. TRIUMPH Investigators.
99. Fox K.A., Steg P.G., Eagle K.A., et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 1892, 2007:297.
100. Webb J.G., Sanborn T.A., Sleeper L.A., et al. Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry. Am Heart J 2001, 141:964.
101. Sleeper L.A., Ramanathan K., Picard M.H., et al. Functional capacity and quality of life following emergency revascularization for cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 2005, 46:266.
102. Singh M., White J., Hasdai D., et al. Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock. J Am Coll Cardiol 2007, 50:1752.